Editorials

Cardinal Health Inc (CAH) filed its fiscal 2026 10-K on August 11 for the year ended June 30, 2026. The company's results confirm a pattern long familiar to healthcare logistics investors: enormous scale generating modest absolute profits, yet producing steady cash returns that fund both debt reduction and shareholder distributions. The real question for value investors is whether the business model's inherent structurally low margins reflect acceptable economics given the moat it derives from scale and working-capital efficiency.

For the year ended June 30, 2026, Cardinal Health reported total revenues of $254.2 billion, up 14.2% from the prior year. This is a staggering volume of merchandise moved through the U.S. healthcare system. Yet cost of goods sold was $244.5 billion, leaving a gross profit of $9.8 billion, or just 3.85% of revenue. That thin margin reflects the brutal commoditized nature of pharmaceutical and medical-device distribution. After $6.1 billion in selling, general and administrative expense, operating income reached $2.6 billion, an operating margin of just 1.03%.

For perspective, operating margins of 3.8% before SG&A represent the typical outcome in high-velocity logistics: the business survives on volume, not on pricing power. Yet this is no accident. Pharmaceutical distribution in particular is a regulatory monopoly-lite: the business is capital-intensive (warehouses, technology, logistics infrastructure), requires uninterrupted supply to hospitals and pharmacies, and faces strong customer concentration among large hospital systems and pharmacy chains. Disrupting this supply chain is not a casual matter.

Profit as reported ($1.7 billion net income for FY2026) understates the business's true cash-generative power. The cash flow statement reveals the story. Operating cash flow reached $5.2 billion in fiscal 2026, despite volatile quarterly patterns. In Q2 2026 (ended December 31, 2025), Cardinal paid out cash for inventories and receivables management, producing negative cash of $1.8 billion from the change in cash and cash equivalents. Yet the full-year number held firm at $982 million in net cash generation (after all cash activities).

This resilience reflects two dynamics working in Cardinal's favor:

1. Working Capital Leverage: Accounts payable expanded by $3.5 billion during the year. In a high-volume distribution business, payables are a natural source of financing. Suppliers grant payment terms, and with $254 billion in annual throughput, even small extensions of payment windows yield billions in float.

2. Non-Cash Charges: The company recorded $956 million in depreciation and amortization (including $361 million in intangible amortization alone). These add back to operating income in cash flow conversion, boosting the reported cash generation.

Operating cash flow of $5.2 billion against net income of $1.7 billion yields a cash conversion ratio of 3x. Earned a dollar; turned it into three dollars of cash generation. That's the magic of scale in asset-light, working-capital-financed distribution.

Cardinal operates across three reportable segments. Pharmaceutical and Specialty Solutions accounted for $210 billion in revenue (82.6% of the total) and generated $2.0 billion in operating income. GMPD (Global Medical Products Distribution) contributed $12.4 billion in revenue but only $92 million in operating income, an operating margin of 0.7%. All Other segments added $4.5 billion in revenue and $423 million in operating income.

The concentration in pharmaceuticals is pronounced, both as a revenue source and as a profit driver. This reflects Cardinal's core role: it is the nation's largest pharmaceutical wholesale distributor, moving brand-name drugs, generics, and specialty pharmaceuticals from manufacturers to hospitals, pharmacies, and clinics. The low margin on the GMPD segment (medical products) shows that even in healthcare, the pure distribution business gravitates toward compressed economics once competitive parity is achieved.

A striking feature of Cardinal's balance sheet is negative stockholders' equity of -$2.9 billion as of June 30, 2026. This is not a sign of distress but rather a deliberate capital structure choice. The company has funded years of acquisitions, share buybacks, and dividends by borrowing. Long-term debt stands at $7.0 billion, while cash on hand is $4.9 billion, yielding net debt of $2.1 billion.

This inverted equity structure is sustainable because:

• Operating cash flow is strong and recurring ($5.2 billion in FY2026).
• The core business is non-cyclical: people take medications in recessions and expansions alike.
• Working capital is self-financing: payables and receivables cycles fund operations.
• Goodwill and intangibles ($11.4 billion) reflect past acquisitions whose cash flows are folded into operating results.

Yet leverage matters. Interest expense was $348 million in FY2026. At higher interest rates or in a sharp margin compression scenario, this fixed cost becomes a burden. For now, the $5.2 billion in operating cash flow covers interest and debt service comfortably.

Cardinal returned $1.8 billion to shareholders in FY2026: $491 million in dividends and $1.4 billion in share repurchases. It also paid $649 million in capital expenditures (mostly warehouse automation and IT) and spent $1.9 billion on acquisitions (tuck-ins and bolt-ons to expand specialty pharmaceuticals and international presence).

The company is not accumulating cash; it is deploying it. This reflects confidence in the durability of its moat. A business that generates $5 billion in operating cash annually while maintaining flat or declining balance-sheet debt is one that can sustain strategic investment and return capital without financial stress. The 12% year-over-year EPS growth (to $7.27 per diluted share) partly reflects share count reduction from buybacks.

Cardinal Health's competitive position rests on three pillars:

1. Scale: The company operates the largest pharmaceutical distribution network in the United States. Moving $254 billion in annual volume grants negotiating leverage with drug manufacturers, who grant rebates and incentives for volume. It also justifies investment in automation, technology, and logistics infrastructure that smaller competitors cannot match.

2. Regulatory Incumbency: Pharmaceutical distribution in the United States is licensed and regulated. Hospitals and pharmacies cannot casually switch distributors; it requires regulatory approval and operational integration. Cardinal's relationships are sticky.

3. Just-In-Time Efficiency: The working-capital game matters enormously. Cardinal's ability to finance $254 billion in annual throughput with minimal equity capital speaks to deep operational expertise in inventory management, receivables collection, and payable timing. This is not easy to replicate.

These do not produce pricing power or fat margins. But they do produce durable competitive position and recurring cash generation.

Several risks merit investor attention:

Margin Compression from Consolidation: Healthcare provider consolidation (hospital systems merging) increases buyer concentration. Larger buyers demand higher discounts and rebates. This is an ongoing pressure on Cardinal's gross margins.

Generic Drug Deflation: As branded drugs lose patent protection, generic prices fall sharply. Generics now account for roughly 90% of prescriptions in the U.S., and unit economics are thinner than for branded drugs. While volume offsets some pricing loss, margin pressure is structural.

Regulatory and Legal Risk: The opioid settlement obligations (Cardinal paid roughly $6.4 billion in total across multiple settlements in prior years) created one-time drains. Ongoing litigation and regulatory scrutiny of the industry persists.

Debt Service in a Rising Rate Environment: With negative equity and $7 billion in debt, Cardinal is vulnerable if interest rates stay elevated or credit spreads widen.

Technological Disruption: Direct-to-consumer pharmacy models, PillPack, Amazon Pharmacy, and other channels are nibbling at traditional pharmacy distribution volumes. For now, the impact is modest, but it bears watching.

Cardinal Health generates steady, high-quality cash flows from a non-cyclical, scale-driven business. Its $5.2 billion operating cash flow and $2.6 billion operating income reflect a machine that turns a razor-thin margin (3.8%) into substantial absolute dollars through sheer volume.

Yet the business offers no margin expansion story. Operating leverage is limited; gross margins tend to compress over time as buyer power and generic penetration deepen. The valuation multiples reflect this reality: the stock trades at a P/E of 33x (based on $7.23 diluted EPS), and an EV/EBITDA of 16.6x on enterprise value of $56.6 billion. For a company with no growth catalyst and structural margin pressure, these are not discounted valuations.

Cardinal is best viewed as a cash-return story: a mature, well-positioned operator of essential healthcare infrastructure that converts high volumes into steady cash available for debt reduction and shareholder distributions. It is not a growth story, nor does the moat suggest the company will expand margins. The economics are what they are: low margin, high volume, essential service.

Value investors accustomed to analyzing financial stocks or utilities will recognize the framework: stable cash generation, predictable (if not attractive) returns, and durability rather than appreciation. The question is whether the current valuation compensates investors for accepting those terms.